Evaluation of NLC nanoparticles containing hydroquinone, tretinoin, and fluocinolone in the treatment of melasma
- Conditions
- melasma.ChloasmaL81.1
- Registration Number
- IRCT20161207031288N13
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
18 - 50 years old men and women
Case of approximately symmetrical moderate to severe melasma (melasma global severity score(MGSC)>2)
No topical and systemic treatment for melasma during the last 4 weeks
Appropriate general health condition
No change in life style during the study
Signing the consent form of the candidate to participate in the study and the desire to attend regular follow-up courses
Pregnant people or those who plan to become pregnant during the study
People with known allergies to any of the components of the cream
History of using each of the mentioned compounds topically in the last 21 days: Corticosteroids, retinoid compounds, chemical peels, alpha hydroxy acid and beta hydroxy acid compounds
History of systemic use of each of the mentioned compounds in the last 28 days: corticosteroids, tretinoin compounds, interferon types
Patients with rosacea, skin atrophy, acne and eczema
History of use of drugs that increase photosensitivity in the last 3 months
People who have had laser skin peeling or microdermabrasion in the last 3 months
If the doctor of the study determines that the volunteer is not appropriate for this study by some reaons
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified melasma severity index. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: Using mMASI(modified Melasma Severity Index).
- Secondary Outcome Measures
Name Time Method Skin pH. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: MPA 580.;Skin sebum. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: MPA 580.;Skin melanin and erythem. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: MPA 580.;Trance Epidermal Water Lost (TEWL). Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: MPA 580.;Size and value of skin spot. Timepoint: Before intervention, 4 weeks later, 8 weeks after intervention. Method of measurement: Visio face.